Friday, May 27, 2016, 78 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $10.48 to $15,949,248.85.

Highlighted Stocks Traded by Insiders:

Karyopharm Therapeutics (KPTI) - FREE Research Report

Chione Ltd, who is 10% Owner at Karyopharm Therapeutics, sold 46,122 shares at $9.73 on May 27, 2016. Following this transaction, the 10% Owner owned 8.8 million shares meaning that the stake was reduced by 0.52% with the 46,122-share transaction.

The shares most recently traded at $9.71, down $0.02, or 0.22% since the insider transaction. Historical insider transactions for Karyopharm Therapeutics go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 246,122
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 246,122
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 246,122

The average volume for Karyopharm Therapeutics has been 236,900 shares per day over the past 30 days. Karyopharm Therapeutics has a market cap of $345.9 million and is part of the health care sector and drugs industry. Shares are down 27.4% year-to-date as of the close of trading on Friday.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Currently, there are 4 analysts who rate Karyopharm Therapeutics a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on KPTI - FREE

TheStreet Quant Ratings

rates Karyopharm Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, poor profit margins, generally disappointing historical performance in the stock itself and deteriorating net income. Get the full

Karyopharm Therapeutics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cumberland Pharmaceuticals (CPIX) - FREE Research Report

Lawrence Thomas R, who is Director at Cumberland Pharmaceuticals, sold 3,000 shares at $4.55 on May 27, 2016. Following this transaction, the Director owned 48,381 shares meaning that the stake was reduced by 5.84% with the 3,000-share transaction.

Historical insider transactions for Cumberland Pharmaceuticals go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 3,000
  • 24-Week # shares sold: 3,000

The average volume for Cumberland Pharmaceuticals has been 25,700 shares per day over the past 30 days. Cumberland Pharmaceuticals has a market cap of $73.8 million and is part of the health care sector and drugs industry. Shares are down 13.5% year-to-date as of the close of trading on Thursday.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States and internationally. The company has a P/E ratio of 225.5. Currently, there are no analysts who rate Cumberland Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CPIX - FREE

TheStreet Quant Ratings

rates Cumberland Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Cumberland Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

L Brands (LB) - FREE Research Report

Coe Nicholas, who is CEO-Bath and Body Works at L Brands, sold 28,444 shares at $64.59 on May 27, 2016. Following this transaction, the CEO-Bath and Body Works owned 9,333 shares meaning that the stake was reduced by 75.29% with the 28,444-share transaction.

The shares most recently traded at $67.61, up $3.02, or 4.47% since the insider transaction. Historical insider transactions for L Brands go as follows:

  • 4-Week # shares bought: 1,285
  • 4-Week # shares sold: 28,444
  • 12-Week # shares bought: 1,285
  • 12-Week # shares sold: 33,946
  • 24-Week # shares bought: 1,285
  • 24-Week # shares sold: 35,446

The average volume for L Brands has been 3.1 million shares per day over the past 30 days. L Brands has a market cap of $19.5 billion and is part of the services sector and retail industry. Shares are down 29.12% year-to-date as of the close of trading on Friday.

L Brands, Inc. operates as a specialty retailer of women's intimate and other apparel, beauty and personal care products, and accessories. The company operates in three segments: Victoria's Secret, Bath & Body Works, and Victoria's Secret and Bath & Body Works International. The stock currently has a dividend yield of 3.53%. The company has a P/E ratio of 15.9. Currently, there are 10 analysts who rate L Brands a buy, 1 analyst rates it a sell, and 15 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LB - FREE

TheStreet Quant Ratings

rates L Brands as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full

L Brands Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.